<DOC>
	<DOC>NCT02739360</DOC>
	<brief_summary>This study is to provide idelalisib to participants receiving GS-9820 in Gilead-sponsored Study GS-US-315-0102 at the time of study closure.</brief_summary>
	<brief_title>Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3KÎ´ Inhibitor, GS-9820</brief_title>
	<detailed_description />
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Receiving GS9820 in Study GSUS3150102 with objective evidence of clinical benefit Evidence of a personally signed informed consent Known hypersensitivity or intolerance to any of the active substances or excipients in the formulation of idelalisib Toxicities that would preclude initiating therapy with idelalisib prior to enrollment Concurrent participation in another therapeutic clinical trial Ongoing infection, treatment, or prophylaxis for cytomegalovirus (CMV) within the past 28 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>